{
  "abstract": "Background and Importance Dolutegravir/lamivudine (DTG/3TC) dual therapy has emerged as an effective, well-tolerated option for HIV management, simplifying treatment and potentially improving adherence. However, few studies have assessed its performance in real-life settings among patients with suboptimal adherence, a group at higher risk of virological failure. Understanding its effectiveness in this population is essential to optimise treatment strategies and ensure long-term viral suppression.Aim and Objectives This study aimed to evaluate adherence to DTG/3TC in HIV patients and its relationship with treatment effectiveness.Material and Methods A single-centre, observational, retrospective study was conducted including all patients treated with DTG/3TC between January 2024 and January 2025. The mean medication possession ratio (MPR) was calculated using leftover medication counts across at least three consecutive bimonthly dispensations through the Prisma outpatient dispensing module. Patients were stratified into two adherence groups: >90% and <90%. Effectiveness was assessed by achieving an undetectable viral load (VL), with CD4+ T-cell counts above 500/mm 3 considered optimal. Data were obtained from the hospital’s clinical laboratory services. Statistical analysis was performed to compare both adherence groups, calculating p-values to determine statistically significant differences in virological suppression and immunological response.Results A total of 346 patients were included, comprising 266 men (mean age 57.98 ± 9.83 SD) and 80 women (55.01 ± 11.96). Two adherence groups were analysed. Patients with adherence >90% (n=284, 82.08%) showed a mean MPR of 91.6% ± 6.4, with 94.01% (n=267) achieving an undetectable viral load (VL) and 65.14% (n=185) presenting both undetectable VL and CD4+ >500/mm 3. Patients with adherence <90% (n=62, 17.92%) had a mean MPR of 84.2% ± 5.8, with 93.55% (n=58) achieving an undetectable VL and 72.58% (n=45) showing undetectable VL plus CD4+ >500/mm3. No statistically significant differences were observed between adherence groups in virological suppression (p=0.78) or in the proportion of patients achieving both undetectable VL and CD4+ >500/mm3 (p=0.32).Conclusion and Relevance Dolutegravir/lamivudine showed high effectiveness in patients with adherence rates above 90%, and comparable virological suppression in those below 90%. These findings suggest that the regimen maintains robust viral control even with suboptimal adherence. Although confirmation in larger cohorts is needed, DTG/3TC appears to be a resilient therapeutic option across different adherence levels.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "CE Vaquer"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "F Martinez De La Torre"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Clinical Laboratory, Madrid, Spain"
      ],
      "name": "B Otero Galvan"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "F Huecas Jiménez"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "B Fernandez Rubio"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "P Del Palacio García"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "B Bertran De Lis Bartolome"
    },
    {
      "affiliations": [
        "Hospital 12 De Octubre, Pharmacy, Madrid, Spain"
      ],
      "name": "JM Ferrari Piquero"
    }
  ],
  "title": "4CPS-204 Effectiveness of dolutegravir/lamivudine dual therapy in HIV patients with suboptimal adherence rates",
  "uid": "7b676366-e521-5100-9528-8f1b59d97d6b"
}